中国临床实用医学
中國臨床實用醫學
중국림상실용의학
CHINA CLINICAL PRACTICAL MEDICINE
2010年
1期
88-89
,共2页
俞安清%陈效琴%苏丽萍%何先伟%张韩
俞安清%陳效琴%囌麗萍%何先偉%張韓
유안청%진효금%소려평%하선위%장한
乙肝血清标志物%时间分辨荧光免疫技术%荧光定量PCR技术%临床应用
乙肝血清標誌物%時間分辨熒光免疫技術%熒光定量PCR技術%臨床應用
을간혈청표지물%시간분변형광면역기술%형광정량PCR기술%림상응용
Hepatitis B Serum Markers%Time-resolved Fluorescence Immunoassay%Fluorescence Quantitative PCR Technique%Clinical Application
目的 用实时荧光定量PCR检测乙型肝炎患者HBV-DNA结果进行分析,以探讨其临床诊疗意义.方法 对850例临床标本用时间分辨荧光免疫技术定量测定乙肝病毒血清学指标,用荧光定量PCR法检测血标本中的HBV-DNA,并依据乙肝两对半结果进行归类分组.结果 302份HBsAg(+)、HBeAg(+)、HBcAb(+)标本中有261份HBV-DNA为阳性,阳性率为86.4%,其PCR定量拷贝数为(2.21±0.76)×107/ml;321份HBsAg(+)、HBeAb(+)、HBcAb(+)标本有96份HBV-DNA阳性,阳性率达到29.91%,PCR定量拷贝数为(1.69±0.98)×106/ml;32份HBsAg(+)、HBcAb(+)标本中有9份HBV-DNA为阳性,阳性率为28.13%,28份HBeAb(+)、HBcAb(+)标本有4份PCR HBV-DNA阳性,阳性率14.29%;11份HBcAb(+)标本有6份PCR HBV-DNA阳性,阳性率为42.9%;74份HBsAb(+)、HBeAb(+)、HBcAb(+)标本有5份HBV-DNA阳性,阳性率6.75%;13份HBsAb(+)、HBeAb(+)阳性标本有2份PCR HBV-DNA阳性,阳性率为14.3%;12份HBsAb(+)、HBcAb(+)标本有1份HBV-DNA阳性,阳性率7.69%;4份HBsAb(+)的标本HBV-DNA均为阴性,PCR定量拷贝数为＜1.00E×103;24份HBsAg(+)、HBsAb(+)、HBeAg(+)、HBcAb(+)标本中有21份HBV-DNA为阳性,阳性率为87.50%;1份HBsAg(+)标本HBV-DNA均为阳性,阳性率为100%;10份HBsAg(+)、HBsAb(+)、HBeAb(+)、HBcAb(+)标本有3份HBV-DNA均为阳性,阳性率30.00%,其余38例全阴性结果和各少见模式基本见有HBV-DNA的检出.结论 PCR定量测定HBV-DNA可以真实反映体内乙肝病毒感染和复制及病毒载量情况,更有利于临床治疗和疗效观察.
目的 用實時熒光定量PCR檢測乙型肝炎患者HBV-DNA結果進行分析,以探討其臨床診療意義.方法 對850例臨床標本用時間分辨熒光免疫技術定量測定乙肝病毒血清學指標,用熒光定量PCR法檢測血標本中的HBV-DNA,併依據乙肝兩對半結果進行歸類分組.結果 302份HBsAg(+)、HBeAg(+)、HBcAb(+)標本中有261份HBV-DNA為暘性,暘性率為86.4%,其PCR定量拷貝數為(2.21±0.76)×107/ml;321份HBsAg(+)、HBeAb(+)、HBcAb(+)標本有96份HBV-DNA暘性,暘性率達到29.91%,PCR定量拷貝數為(1.69±0.98)×106/ml;32份HBsAg(+)、HBcAb(+)標本中有9份HBV-DNA為暘性,暘性率為28.13%,28份HBeAb(+)、HBcAb(+)標本有4份PCR HBV-DNA暘性,暘性率14.29%;11份HBcAb(+)標本有6份PCR HBV-DNA暘性,暘性率為42.9%;74份HBsAb(+)、HBeAb(+)、HBcAb(+)標本有5份HBV-DNA暘性,暘性率6.75%;13份HBsAb(+)、HBeAb(+)暘性標本有2份PCR HBV-DNA暘性,暘性率為14.3%;12份HBsAb(+)、HBcAb(+)標本有1份HBV-DNA暘性,暘性率7.69%;4份HBsAb(+)的標本HBV-DNA均為陰性,PCR定量拷貝數為＜1.00E×103;24份HBsAg(+)、HBsAb(+)、HBeAg(+)、HBcAb(+)標本中有21份HBV-DNA為暘性,暘性率為87.50%;1份HBsAg(+)標本HBV-DNA均為暘性,暘性率為100%;10份HBsAg(+)、HBsAb(+)、HBeAb(+)、HBcAb(+)標本有3份HBV-DNA均為暘性,暘性率30.00%,其餘38例全陰性結果和各少見模式基本見有HBV-DNA的檢齣.結論 PCR定量測定HBV-DNA可以真實反映體內乙肝病毒感染和複製及病毒載量情況,更有利于臨床治療和療效觀察.
목적 용실시형광정량PCR검측을형간염환자HBV-DNA결과진행분석,이탐토기림상진료의의.방법 대850례림상표본용시간분변형광면역기술정량측정을간병독혈청학지표,용형광정량PCR법검측혈표본중적HBV-DNA,병의거을간량대반결과진행귀류분조.결과 302빈HBsAg(+)、HBeAg(+)、HBcAb(+)표본중유261빈HBV-DNA위양성,양성솔위86.4%,기PCR정량고패수위(2.21±0.76)×107/ml;321빈HBsAg(+)、HBeAb(+)、HBcAb(+)표본유96빈HBV-DNA양성,양성솔체도29.91%,PCR정량고패수위(1.69±0.98)×106/ml;32빈HBsAg(+)、HBcAb(+)표본중유9빈HBV-DNA위양성,양성솔위28.13%,28빈HBeAb(+)、HBcAb(+)표본유4빈PCR HBV-DNA양성,양성솔14.29%;11빈HBcAb(+)표본유6빈PCR HBV-DNA양성,양성솔위42.9%;74빈HBsAb(+)、HBeAb(+)、HBcAb(+)표본유5빈HBV-DNA양성,양성솔6.75%;13빈HBsAb(+)、HBeAb(+)양성표본유2빈PCR HBV-DNA양성,양성솔위14.3%;12빈HBsAb(+)、HBcAb(+)표본유1빈HBV-DNA양성,양성솔7.69%;4빈HBsAb(+)적표본HBV-DNA균위음성,PCR정량고패수위＜1.00E×103;24빈HBsAg(+)、HBsAb(+)、HBeAg(+)、HBcAb(+)표본중유21빈HBV-DNA위양성,양성솔위87.50%;1빈HBsAg(+)표본HBV-DNA균위양성,양성솔위100%;10빈HBsAg(+)、HBsAb(+)、HBeAb(+)、HBcAb(+)표본유3빈HBV-DNA균위양성,양성솔30.00%,기여38례전음성결과화각소견모식기본견유HBV-DNA적검출.결론 PCR정량측정HBV-DNA가이진실반영체내을간병독감염화복제급병독재량정황,경유리우림상치료화료효관찰.
Objective To analyze HBV-DNA results of hepatitis B patients using real-time fluorescence quantitative PCR detection and to explore the significance of their clinical treatment. Methods 850 cases of clinical specimens were detected by time-resolved fluorescence immunoassay quantitative determination and fluorescent quantitative PCR assay detected HBV-DNA of blood samples and the results were divided groups. Results There were 261 positive in group that the HBsAg( + ), HBeAg ( + )and HBcAb ( + )were positive and positive rate was 86.4% (261/302)and its quantitative PCR for copy number was(2. 21 ± 0. 76) × 107/ml.There were 96 positive in group that the HBsAg( + ) ,HBeAb( + )and HBcAb( + )were positive and the positive rate was 29.91% (96/321)and its quantitative PCR for copy number was( 1.69 ± 0. 98) × 106/ml. There were 9 were positive in group that the HBsAg( + )and HBcAb( + )were positive and positive rate was 28. 13% (9/32). There were 4 positive in group that the HBeAb ( + ) and HBcAb ( + ) were positive and positive rate was 14. 29% (4/28). There were 6 positive in group that the HBcAb( + )was positive and the positive rate was 42.9% (6/11). There were 5 positive in group that the HBsAb( + ), HBeAb( + ) and HBcAb( + ) were positive and the positive rate was 6. 75% (5/74). There were 2 positive in group that HBsAb( + )and HBeAb( + )positive and the positive rate was 14. 3% (2/13). There were 1 positive in group that HBsAb( + ) and HBcAb ( + )were positive and a positive rate was 7.69% (1/12). 4 were negative in group of HBsAb( + ). There were 21 positive in the group that were HBsAg( + ), HBsAb( + ), HBeAg( + )and HBcAb( + )were positive and the positive rate was 87.50% (21/24). The positive rate was 100% 1 in group of HBsAg( + ). There were 3 positive in group that HBsAg( + ), HBsAb ( + ), HBeAb ( + ) and HBcAb ( + ) were positive and the positive rate was 30. 00% (3/10). The remaining 38 patients were negative results. Conclusion PCR quantitative determination of HBV-DNA can be a true reflection of hepatitis B virus infection and replication in vivo and more conducive to clinical treatment and efficacy.
